Trial Profile
Phase 2 trial of ERY001 in the patients with first line pancreatic cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs ERY-ASP (Primary)
- Indications Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors ERYtech Pharma
- 24 Jun 2018 According to an ERYtech Pharma media release, this company sponsored, proof of concept study is expected to start in 2018, with patients enrollment to commence in the first half of 2019.
- 13 Apr 2018 New trial record